Bile acids are synthesised in the liver, transformed by gut bacteria, and reabsorbed to regulate cholesterol metabolism, fat absorption, gut motility, and systemic hormonal signalling. When this cycle is disrupted — by dysbiosis, by impaired liver function, by poor dietary fat — the consequences appear across multiple systems simultaneously. And almost nobody is measuring it.
If you ask most people what bile does, the answer — if they have one at all — is something like “it breaks down fat.” This is true but deeply incomplete. Bile acids are among the most physiologically versatile molecules in the body. They are synthesised from cholesterol in the liver, concentrated in the gallbladder, secreted into the small intestine in response to fat ingestion, modified by gut bacteria into secondary bile acids, reabsorbed in the terminal ileum, and returned to the liver for recycling. This cycle — the enterohepatic circulation — operates continuously and has consequences far beyond fat digestion.
Bile acids are signalling molecules. They activate nuclear receptors (FXR, TGR5) that regulate cholesterol metabolism, glucose homeostasis, thyroid hormone activation, and gut motility. They shape the composition of the gut microbiome by creating an environment in which certain bacteria thrive and others are suppressed. They influence the integrity of the intestinal barrier. They determine how effectively fat-soluble vitamins — A, D, E, K — are absorbed.
When the enterohepatic bile acid cycle is disrupted — through dysbiosis, gallbladder dysfunction, impaired liver synthesis, or dietary insufficiency — the effects are systemic, multifaceted, and often attributed to other causes. Fat-soluble vitamin deficiency. Elevated cholesterol. Bloating and fatty stool. Hormonal dysregulation. Thyroid conversion impairment. These are all potential downstream consequences of a conversation between the gut and the liver that nobody is monitoring.
Most abundant primary bile acid. Conjugated with glycine or taurine. Converted to deoxycholic acid (DCA) by gut bacteria.
Second primary bile acid. Most potent FXR activator. Converted to lithocholic acid (LCA) and ursodeoxycholic acid (UDCA) by bacteria.
Produced from cholic acid by bacterial 7α-dehydroxylation. Potent TGR5 agonist — stimulates GLP-1. Also associated with intestinal inflammation at high concentrations.
Therapeutically used for liver disease (PBC, primary sclerosing cholangitis). Anti-inflammatory, hepatoprotective. Produced endogenously by specific gut bacteria in small amounts.
The transformation of primary to secondary bile acids requires specific gut bacterial species with 7α-dehydroxylase activity. When dysbiosis depletes these species — through antibiotics, poor diet, or pathogen overgrowth — the bile acid pool shifts toward primary bile acids and away from secondary bile acids. This has cascading consequences.
Reduced secondary bile acid production means reduced TGR5 activation, which reduces GLP-1 secretion. Less GLP-1 means impaired satiety signalling, less insulin sensitisation, and potentially greater appetite. This is one of several mechanisms through which gut dysbiosis contributes to metabolic dysregulation and weight difficulties — entirely independently of caloric intake.
Certain bacteria, when overgrown, produce bile salt hydrolase (BSH) enzymes that excessively deconjugate bile acids in the small intestine rather than the colon. Deconjugated bile acids in the small intestine are less effective at fat emulsification, are directly irritant to the small intestinal epithelium, and can drive bile acid malabsorption. This is part of the mechanism in SIBO — bacterial overgrowth in the small intestine creates premature deconjugation and impairs fat and fat-soluble vitamin absorption.
This is where the bile acid story intersects directly with the GI-MAP and oestrogen metabolism. Beta-glucuronidase is an enzyme produced by certain gut bacteria that deconjugates oestrogen glucuronides in the large intestine. Conjugated oestrogens are supposed to be excreted in faeces — they have been processed by the liver and marked for elimination. Beta-glucuronidase cleaves the glucuronic acid group, liberating unconjugated oestrogen which is then reabsorbed into systemic circulation via the enterohepatic route.
Elevated beta-glucuronidase on GI-MAP is a marker of excessive oestrogen recirculation. It is associated with oestrogen dominance, increased breast cancer risk, PMS, endometriosis, and hormonal symptoms in women. In men, it contributes to elevated oestradiol and the hormonal imbalance patterns seen in metabolic syndrome.
Beta-glucuronidase activity is increased by dysbiosis (particularly certain Bacteroides species and Clostridium), by low dietary fibre (fibre reduces transit time and limits bacterial oestrogen deconjugation), and by high dietary fat without adequate fibre. It is reduced by calcium D-glucarate (a natural compound found in fruits and vegetables that inhibits beta-glucuronidase activity) and by dietary patterns that support diverse gut flora.
The connection to bile acids: the same dysbiosis that disrupts bile acid transformation also elevates beta-glucuronidase. These are not separate problems — they are different expressions of the same underlying disruption in the gut microbial ecosystem.
Vitamins A, D, E, and K2 are fat-soluble. Their intestinal absorption requires the micellar emulsification that bile acids provide. When bile flow is impaired — through gallbladder dysfunction, biliary stasis, or inadequate bile acid secretion — fat-soluble vitamin absorption is compromised even when dietary intake is adequate.
Vitamin D deficiency is pandemic in the UK, and latitude and sun exposure rightly get most of the attention. But impaired bile acid function is a less-discussed contributor to vitamin D insufficiency that is entirely independent of sun exposure. A client supplementing 4,000 IU vitamin D daily with persistently low 25-OH vitamin D levels on blood chemistry should be assessed for fat malabsorption, including bile acid adequacy.
Vitamin K2 is the fat-soluble vitamin responsible for directing calcium to bone and away from arterial walls. Its absorption depends entirely on micellar solubilisation via bile. In clients with gallbladder removal (cholecystectomy), bile acid secretion becomes continuous and unregulated rather than pulsatile in response to meals — altering the micellar environment for fat-soluble vitamin absorption in ways that are rarely discussed post-surgically.
Bile acids activate TGR5 receptors in brown adipose tissue and skeletal muscle, stimulating intracellular thyroid hormone activation — specifically the conversion of T4 to active T3 via type 2 deiodinase. Impaired bile acid signalling through TGR5 therefore reduces peripheral T4 to T3 conversion, contributing to low T3 patterns on thyroid panels even when TSH is normal and T4 is adequate. This is a specific mechanism connecting gut bile acid function to thyroid status — and it is almost never considered in standard thyroid assessment.
Approximately 70,000 cholecystectomies (gallbladder removal) are performed in the UK annually. Post-cholecystectomy, bile drips continuously into the small intestine rather than being stored and released in concentrated bursts in response to meals. The consequences — diarrhoea, fat malabsorption, bloating, altered gut motility, impaired fat-soluble vitamin absorption — are common and often poorly managed post-surgically.
For post-cholecystectomy clients, bile acid support (ox bile supplementation with meals, digestive enzyme combinations including lipase, and dietary fat modulation) is clinically relevant and often produces significant symptomatic improvement. This is rarely offered in standard post-surgical care.
The liver synthesises bile from cholesterol. The gut microbiome transforms it into its most biologically active forms. The terminal ileum reclaims 95% of it for reuse. Three organs, one continuous conversation. When the conversation breaks down, the effects appear in your blood work, your hormone panel, your thyroid results, and your gut symptoms — and the connection is almost never made.
GI-MAP: Beta-glucuronidase (oestrogen recirculation via enterohepatic route), steatocrit (fat in stool — indicator of fat malabsorption), Clostridium species (key secondary bile acid transformers), Bacteroides (BSH-producing species relevant to deconjugation), elastase-1 (fat digestion capacity — distinguishes pancreatic from biliary cause of fat malabsorption). Blood chemistry: Total cholesterol and LDL (elevated if cholesterol-to-bile-acid conversion is impaired), GGT (sensitive liver stress marker, elevated in bile flow disruption), ALP (bone fraction versus liver fraction — bile-relevant liver fraction elevates in cholestasis), vitamin D 25-OH (low despite supplementation suggests fat malabsorption), vitamin A (less commonly tested but clinically relevant). DUTCH: Oestrogen metabolite pathways — particularly 2-OH vs 16-OH pathway balance and 2-MeOE1 (methylation of oestrogens) — contextualisied alongside GI-MAP beta-glucuronidase to distinguish hepatic from intestinal oestrogen handling issues. Metabolomix+ OAT: Fat-soluble vitamin markers, fatty acid profile (omega-3/6 balance reflects absorption efficiency), and specific bacterial metabolites that reflect microbial bile acid transformation activity.
The GI-MAP, blood chemistry, and DUTCH together map the bile acid cycle from liver synthesis to gut transformation to oestrogen recirculation. Ask the DH Concierge what this means for your specific pattern of symptoms.
Ask the Concierge → Book a discovery call